Peter Gerhardsson, appointed as the senior advisor at GlucoModicum, has forty years of expertise in the medtech and pharmaceutical industries.
FREMONT, CA: GlucoModicum appoints Peter Gerhardsson as a Senior Advisor to GlucoModicum. GlucoModicum's needle-free magneto hydrodynamic technology is revolutionising glucose monitoring. Its patented technology has the potential to completely transform how individuals track their health, enabling people to live better lives by offering solutions that are precise, accessible, and needle-free.
Mr. Gerhardsson has 40 years of experience in the medical device and pharmaceutical industries, focusing on diabetic therapy. Mr Gerhardsson was Vice President of International Business Development at Dexcom for a decade. During that time, he built a global network of distributors for Dexcom's Continuous Glucose Monitoring (CGM) system, resulting in significant revenue and market access. He was also in charge of Dexcom's Emerging Markets market and business growth.
Mr. Gerhardsson began his career with Novo Nordisk, a worldwide healthcare business based in Denmark, where he worked for twenty years in various marketing and sales roles. In 2000, he joined MiniMed, where he was in charge of Medtronic's European diabetic business groups. Mr Gerhardsson left Dexcom to join the Institute for Applied Economics and Health Research in Copenhagen, which conducts evidence-based research for healthcare decision-making, the pharmaceutical sector, and environmental policy. Mr. Gerhardsson now works as an independent consultant. He also has a Master of Science degree from Lund University in Sweden and a marketing and economics diploma from Lund University's Executive Foundation and an E-MBA from Stanford University.
Jokke Maki, Chief Executive Officer of GlucoModicum, commented: “Peter’s deep knowledge and network in the continuous glucose monitory space will be invaluable to GlucoModicum as we develop our needle-free glucose monitoring technology. Attracting someone of Peters stature to help us bring our unique MHD approach to people in need as soon as possible, is a great validation and we very much look forward to working with him closely.”
Peter Gerhardsson added, “GlucoModicums MHD technology has the potential to transform the way people monitor their blood glucose levels and manage their diabetes, removing the need for needles and providing freedom to patients globally. I am looking forward to getting started and working with Jokke and the rest of the talented GlucoModicum team.”